Background
Th e Czech Society of Cardiology was founded in 1929 and is the third oldest cardiology society in the world. In 2009, we celebrate the 80th anniversary of the founding of our society. To mark this occasion, I was invited by Michael Aschermann -Editor-in-Chief of Cor et Vasa -to contribute by a special article reviewing all randomized clinical trials with the acronym "PRAGUE". I accepted with pleasure and invited Harry Suryapranata to join me. Harry Suryapranata was my PCI teacher and my research inspiration in my early steps in the fi eld of interventional cardio logy. Dr. Suryapranata was also one of the co-authors of the fi rst PRAGUE trial manuscript. In 2007, he was awarded (on behalf of the Zwolle group) -for his overall contribution to the development of primary PCI -the "Andreas Gruntzig Lecture and Award" during the annual congress of the European Society of Cardiology (Figure 1 ). In fact, our trials (fi rst Zwolle and fi rst Prague) shared quite a lot of similarities, i.e.:
1. Geography: the size of our network area served by medical emergency service 2. Th e number of population in our catchment area (1.5 million in the Zwolle area) 3. Th e number of referral hospitals (17 in the Zwolle area) 4. Reduction in total time delay by fast tract facilities: 215 to 178 min Below, the past, present and future randomized clinical trials from the "PRAGUE Study Group workshop" are presented in an overview ( Table 1) . Also the VINO trial (conducted within the same network and not named by a "PRAGUE" acronym just because we did not expect more trials in this series at the beginning) is included.
Before describing individual trials, we would like to look back at how all this happened. During my (P.W.) PCI training in Zwolle (NL) between 1992 and 1994, I was fascinated by the large benefi t seen in STEMI patients treated by primary PCI. Th e Zwolle group (Figure 1 ) was pioneering primary PCI for STEMI in those years. Aft er returning to my hospital at Královské Vinohrady (a quarter of Prague), we decided with my colleagues to stop completely thrombo lytic treatment in our Cardiocenter and since October 5, 1995 all STEMI patients were treated by primary PCI. Th e STEMI in-hospital mortality fell dramatically from 11% (1994) to 4% (1996) . Th us, we started to think about the ways how to off er such benefi t also to patients living outside Prague, who present with their STEMI to a local non-PCI hospital. Th e design of the fi rst PRAGUE study was prepared. It was called simply "PRAGUE" (not PRAGUE-1), because we did not expect additional studies to follow. Th e acronym "PRAGUE" means in full text "PRimary Angioplasty for patients from General non-PCI hospitals transferred to PCI Units with or without Emergency thrombolysis".
The PRAGUE study protocol was prepared and application for a research grant was submitted to the Czech Ministry of Health -Internal Grant Agency. Th e result of this application came as a bad surprise for us: I was invited to attend the meeting of the Scientifi c Board of the Ministry and to explain how it was possible that we were planning a research project extremely dangerous for patients who were most likely to die during inter-hospital transfers from non-PCI hospitals to PCI centers. Th e board agreed that such a dangerous and unethical project should not be supported by a grant. Th is ministerial scientifi c board went even further and proposed that we should not be allowed to run the project (even without the grant support). Fortunately, before writing such a prohibitive decision they consulted the Board of the Czech Society of Cardiology for its view. Th e Czech Society of Cardiology Board met and aft er a long discussion (based on the evidence available by 1996) decided by 12:1 votes to support the PRAGUE Study project (Figures 2-4 ). Th us, the fi nal decision of the Health Ministry was to refuse fi nancial support, but to allow us to run the trial if we wished so without a research grant. A small group called "Prague Study Group" (P. Widimský, L. Groch, M. Želízko, M. Aschermann, T. Buděšínský) agreed to run the project even without fi nancial support. Th e protocol compared three standard treatment options, which were routinely reimbursed to the hospitals by insurance companies and thus no money was necessary for a simple design trial to start. Th e local ethics committees of all 21 participating hospitals approved the study protocol. Data collection and analysis were done by physicians from the 21 participating hospitals enthusiastically based on a simple case report form.
Th e following part briefl y describes the completed and the ongoing PRAGUE trials.
PRAGUE-1 trial
Th is trial was described at the introduction and is widely known, thus we provide here just the reference to the main manuscript and a picture ( Figure 5 ) of one of our fi rst successful primary PCI patients on top of Kala Pattar (5465 m above sea level) with Mount Everest seen in the back.
VINO trial
Shortly aft er the beginning of the PRAGUE-1 study, we started preparations of the protocol for a smaller study testing the role of emergent coronary angiography (± PCI) in non-ST segment elevation acute myocardial infarction within 24 hours aft er admission. Th e results of this small 
PRAGUE-2 trial
Aft er the end of the PRAGUE-1 study in 1999, all authors considered the answer to be very clear: primary PCI should be the treatment of choice for all STEMI patients, even when they need inter-hospital transport. However, the Czech health care authorities and, also, many "thrombolysis-lovers" among cardiologists criticized the study for its small size and refused to adopt the study results for daily practice. Th us, we decided to run a larger (truly nationwide) randomized study with the primary end-point being all-cause mortality. Fift y-one Czech hospitals (approx. half of the country) agreed to participate. Th is PRAGUE-2 study enrolled 850 patients and was terminated prematurely for two reasons: (1) marked benefi t (2.5-fold decrease in mortality) from the primary PCI strategy among patients randomized >3 hours aft er symptom onset and, (2) the growing resistance of the non-PCI hospitals to randomize patients to the thrombolytic arm. Th e fact that the preliminary study results (before they were even analyzed and published!) convinced the non-PCI hospitals to transfer all their STEMI patients routinely for primary PCI, was the most important trigger of the fast development aft er the end of the PRAGUE-2 study: thrombolysis was almost completely abandoned in the whole country within the fi rst year aft er PRAGUE-2. In those few counties (regions) still not having PCI facilities new catheterization labs were opened and interventional cardiologists from experienced centers were invited to start the primary PCI service. In 2004, the whole country was covered by primary PCI services with only one exception -the last region (Vysočina) opened its PCI center later (2007) . 
PRAGUE-3 trial
Th e PRAGUE-3 trial was designed to test whether patients presenting with STEMI or Q-MI > 24 hours aft er symptom onset should undergo immediate coronary angiography ± PCI or should be rather treated conservatively. Th e design was thus similar to an international OAT trial, performed several years later. Unfortunately, the PRAGUE-3 trial was stopped prematurely due to its very low patient recruitment rate (only 44 patients enrolled during 1.5 years in 4 participating centers). Th ere was no diff erence between the two treatment groups and the results were never published.
PRAGUE-4 trial
Th e PRAGUE-4 trial analyzed whether off -pump surgery is superior to on-pump surgery in unselected patients undergoing CABG. Th e surgical results were slightly positive for off -pump procedures, while one-year angiographic controls for bypass graft patency were slightly favoring on-pump surgery.
Widimský P, Straka Z, Štros P, Jirásek K, Dvořák J, Votava J, et al. One-year PRAGUE-4 trial. Circulation 2004; 110(22):3418-23. Straka Z, Widimský P, Jirásek K, Štros P, Votava J, Vaněk T, et al. Off -pump versus on-pump 
PRAGUE-5 trial
Th is small trial randomized patients with single-vessel coronary artery disease aft er successful primary PCI into a very early discharge group and a standard discharge group. Results showed feasibility of very early (aft er 29 hours) discharge in a highly selected low-risk STEMI population. PRAGUE-5". Int Heart J 2008; 49(6) :653-9.
PRAGUE-6 trial
Th e trial is still ongoing, with the end of enrollment expected in late 2009 or early 2010. Patients with EuroSCORE ≥ 6 scheduled for bypass surgery are randomized between off -pump versus on-pump surgery.
PRAGUE-7 trial
Patients with cardiogenic shock were randomized between routine early (upfront, before coronary angiography) abciximab and selective abciximab (given only to some patients based on CAG fi nding, i.e. during PCI). Th is trial was presented during the Hot Line session at the ESC Congress 2009 in Barcelona. Th e manuscript is currently undergoing peer review.
PRAGUE-8 trial
Th e ESC guidelines for PCI published in 2005 recommended to pre-treat all patients undergoing elective coronary angiography for chronic stable coronary artery disease by clopidogrel 300-600 mg. We did not believe in this strategy and thus we decided to design a randomized trial comparing this guidelines-recommended strategy with our routinely used strategy (no clopidogrel before angiography, clopidogrel at loading dose given only before PCI, i.e., based on the angiographic fi nding). Th e trial confi rmed that our strategy is at least equal (or even slightly better) than the guideline-recommended approach.
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PRAGUE-9 trial
Th e most ambitious, but also the most diffi cult of the new generation (aft er PRAGUE-5) of our trials. Patients with coronary artery disease indicated for revascularization and having also ischemic or degenerative mitral regurgitation were randomized to either complete surgical treatment (bypass graft ing + mitral valvuloplasty) or multivessel PCI alone (leaving mitral regurgitation for conservative treatment). Although 8 Czech tertiary cardiac centers
